These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 3197748)

  • 1. Estimating reduced availability due to first pass elimination from relative total clearance and renal clearance.
    Brockmeier D
    Eur J Clin Pharmacol; 1988; 35(4):397-400. PubMed ID: 3197748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A convenient method for estimating the quantity of drug eliminated by the routes other than hepatic metabolism and renal excretion and the fraction of drug that reaches the "first pass" after oral administration.
    Berezhkovskiy LM
    J Pharm Sci; 2006 Apr; 95(4):828-33. PubMed ID: 16489605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug availability to noneliminating tissues and sites of action following an intravenous dose.
    Cutler DJ
    J Pharm Sci; 1986 Dec; 75(12):1141-4. PubMed ID: 3559922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Model independent derivation of general equations for the "first-pass" effect and extra-hepatic drug elimination.
    Vaughan
    Eur J Clin Pharmacol; 1977; 11(1):57-64. PubMed ID: 832659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of melatonin in man: first pass hepatic metabolism.
    Lane EA; Moss HB
    J Clin Endocrinol Metab; 1985 Dec; 61(6):1214-6. PubMed ID: 4055987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioavailability under variable renal clearance conditions.
    Oie S; Jung D
    J Pharm Sci; 1979 Jan; 68(1):128-9. PubMed ID: 758455
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacokinetic transfer functions and generalized clearances.
    Siegel RA
    J Pharmacokinet Biopharm; 1986 Oct; 14(5):511-21. PubMed ID: 3806373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Criticism of pharmacokinetic clearance concepts.
    Keller F; Schoole J
    Int J Clin Pharmacol Ther Toxicol; 1983 Nov; 21(11):563-8. PubMed ID: 6654532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biased estimates of nonrenal clearance.
    Hinderling PH
    J Pharm Sci; 2001 Jul; 90(7):960-6. PubMed ID: 11458343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can non-renal clearance and/or bioavailability of drugs be assessed reliably in renal impairment studies with oral drug administration?
    Yu Y; Hinderling PH
    Int J Clin Pharmacol Ther; 2024 Mar; 62(3):129-141. PubMed ID: 38174884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. On the pharmacokinetics of phenacetin in man.
    Raaflaub J; Dubach UC
    Eur J Clin Pharmacol; 1975 Apr; 8(3-4):261-5. PubMed ID: 1233222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered hepatic blood flow and drug disposition.
    Nies AS; Shand DG; Wilkinson GR
    Clin Pharmacokinet; 1976; 1(2):135-55. PubMed ID: 13954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Commentary: a physiological approach to hepatic drug clearance.
    Wilkinson GR; Shand DG
    Clin Pharmacol Ther; 1975 Oct; 18(4):377-90. PubMed ID: 1164821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A general equation for the ratio of the areas below the blood or plasma concentration time-curves following intravenous and oral drug administration and its application to inter-subject variations in drug elimination.
    Vaughan DP; Trainor A
    Br J Clin Pharmacol; 1975 Jun; 2(3):239-50. PubMed ID: 1234504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein binding and drug clearance.
    Rowland M
    Clin Pharmacokinet; 1984 Jan; 9 Suppl 1():10-7. PubMed ID: 6705422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered disposition and availability of cimetidine in liver cirrhotic patients.
    Gugler R; Müller-Liebenau B; Somogyi A
    Br J Clin Pharmacol; 1982 Sep; 14(3):421-30. PubMed ID: 7126415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new model-independent physiological approach to study hepatic drug clearance and its applications.
    Chiou WL
    Int J Clin Pharmacol Ther Toxicol; 1984 Nov; 22(11):577-90. PubMed ID: 6389376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interactions and non-interactions with ranitidine.
    Kirch W; Hoensch H; Janisch HD
    Clin Pharmacokinet; 1984; 9(6):493-510. PubMed ID: 6096071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dependence of renal clearance on urine flow: a mathematical model and its application.
    Tang-Liu DD; Tozer TN; Riegelman S
    J Pharm Sci; 1983 Feb; 72(2):154-8. PubMed ID: 6834253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A dispersion model of hepatic elimination: 2. Steady-state considerations--influence of hepatic blood flow, binding within blood, and hepatocellular enzyme activity.
    Roberts MS; Rowland M
    J Pharmacokinet Biopharm; 1986 Jun; 14(3):261-88. PubMed ID: 3783447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.